These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10837632)

  • 1. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo.
    Cullis PR; Chonn A; Semple SC
    Adv Drug Deliv Rev; 1998 Jun; 32(1-2):3-17. PubMed ID: 10837632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.
    Semple SC; Harasym TO; Clow KA; Ansell SM; Klimuk SK; Hope MJ
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1020-6. PubMed ID: 15525796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of temoporfin-loaded liposome formulations: correlation of liposome and temoporfin blood concentration.
    Decker C; Schubert H; May S; Fahr A
    J Control Release; 2013 Mar; 166(3):277-85. PubMed ID: 23313962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors.
    Ishida T; Harashima H; Kiwada H
    Curr Drug Metab; 2001 Dec; 2(4):397-409. PubMed ID: 11766990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of dose on liposome clearance: critical role of blood proteins.
    Oja CD; Semple SC; Chonn A; Cullis PR
    Biochim Biophys Acta; 1996 May; 1281(1):31-7. PubMed ID: 8652601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Liposomes as drug carrier systems. Preparation, classification and therapeutic advantages of liposomes].
    Budai M; Szógyi M
    Acta Pharm Hung; 2001; 71(1):114-8. PubMed ID: 11769091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in vitro assay based on surface plasmon resonance to predict the in vivo circulation kinetics of liposomes.
    Crielaard BJ; Yousefi A; Schillemans JP; Vermehren C; Buyens K; Braeckmans K; Lammers T; Storm G
    J Control Release; 2011 Dec; 156(3):307-14. PubMed ID: 21803084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted liposomal drug delivery in cancer.
    Medina OP; Zhu Y; Kairemo K
    Curr Pharm Des; 2004; 10(24):2981-9. PubMed ID: 15379663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor versus non-receptor mediated clearance of liposomes.
    Kamps JA; Scherphof GL
    Adv Drug Deliv Rev; 1998 Jun; 32(1-2):81-97. PubMed ID: 10837637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.
    Dos Santos N; Allen C; Doppen AM; Anantha M; Cox KA; Gallagher RC; Karlsson G; Edwards K; Kenner G; Samuels L; Webb MS; Bally MB
    Biochim Biophys Acta; 2007 Jun; 1768(6):1367-77. PubMed ID: 17400180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in liposome technologies and their applications for systemic gene delivery.
    Cullis PR; Chonn A
    Adv Drug Deliv Rev; 1998 Mar; 30(1-3):73-83. PubMed ID: 10837603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends and developments in liposome drug delivery systems.
    Lian T; Ho RJ
    J Pharm Sci; 2001 Jun; 90(6):667-80. PubMed ID: 11357170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona.
    Caracciolo G
    Nanoscale; 2018 Mar; 10(9):4167-4172. PubMed ID: 29450412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release-/transfer-assay.
    Hinna AH; Hupfeld S; Kuntsche J; Bauer-Brandl A; Brandl M
    J Control Release; 2016 Jun; 232():228-37. PubMed ID: 27112112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems.
    Patel GB; Sprott GD
    Crit Rev Biotechnol; 1999; 19(4):317-57. PubMed ID: 10723627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of liposome characteristics and dose on the pharmacokinetics of liposomes coated with poly(amino acid)s.
    Romberg B; Oussoren C; Snel CJ; Hennink WE; Storm G
    Pharm Res; 2007 Dec; 24(12):2394-401. PubMed ID: 17674159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entrapment of small molecules and nucleic acid-based drugs in liposomes.
    Fenske DB; Cullis PR
    Methods Enzymol; 2005; 391():7-40. PubMed ID: 15721372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane modification by negatively charged stearyl-polyoxyethylene derivatives for thermosensitive liposomes: reduced liposomal aggregation and avoidance of reticuloendothelial system uptake.
    Iga K; Ohkouchi K; Ogawa Y; Toguchi H
    J Drug Target; 1994; 2(3):259-67. PubMed ID: 7812694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.